{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Subject is lost to follow-up despite reasonable efforts by the investigator to locate the subject.', 'Death.', 'Subjects who discontinue treatment prior to radiological disease progression will enter the post', 'treatment follow-up period and continue to undergo imaging assessments every 56 days ( 7 days)', 'until PFS1 is documented by radiological disease progression or the subject starts another', 'anticancer treatment, whichever occurs earlier.', 'Following PFS1, subjects will enter the long-term follow up period and be followed per', 'institutional guidelines but not less than every 3 months from the date of the follow-up visit for', 'survival status and progression on next line therapy until PFS2 is documented or the subject starts', 'another anticancer treatment, whichever occurs earlier.', 'Subjects will then enter the survival follow-up period. Subjects will be followed every 3 months', 'for survival status until any of the discontinuation criteria for os are met. The subject will be', 'discontinued from the OS post treatment follow-up period if any of the following occur:', 'Subject declines further study participation (i.e., withdraws consent).', 'Subject is lost to follow-up despite reasonable efforts by the investigator to locate the subject.', 'Death.', 'Study termination.', 'Concomitant Medication Restrictions or Requirements:', 'If the investigator determines that any of the following medications are deemed necessary to', 'provide adequate medical support to the subject, the subject must be withdrawn from further', 'administration of the study treatment:', 'Other investigational drugs', 'Chemotherapy or other medications intended for antitumor activity. This does not apply to', 'subjects with a history of breast cancer on adjuvant endocrine therapy, or to subjects on agents', 'intended for the treatment of bone metastasis (e.g., bisphosphonates, or RANK ligand', 'inhibitors).', 'Radiation therapy', 'Note: Radiation therapy to a symptomatic solitary lesion or to the bone may be considered on', 'an exceptional case-by-case basis after consultation with Sponsor. The radiated lesion must be', 'a non-target lesion per RECIST V1.1 and the subject must have clear measurable disease', 'outside the radiated field.', 'Arm A (Enfortumab vedotin)', 'Subjects who are receiving strong cytochrome P450 (CYP)3A4 inhibitors or P-pg inhibitors', 'concomitantly with EV should be closely monitored for adverse reactions.', 'Arm B (Docetaxel)', 'Concomitant use of drugs that strongly inhibit or induce CYP3A4 may affect exposure to', 'docetaxel and should be avoided.', 'Arm B (Vinflunine)', 'Strong inhibitors or inducers of the CYP3A4 enzymes for subjects receiving vinflunine should', 'be avoided.', 'QT/QTc interval prolonging medicinal products should be avoided.', 'Arm B (Paclitaxel)', 'Caution should be exercised when paclitaxel is administered with strong inhibitors or inducers', 'of CYP3A4 and CYP2C8.', '14 Sep 2020', 'Astellas', 'Page 28 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Please refer to the local package insert for concomitant medication restrictions or requirements for', 'docetaxel, paclitaxel and vinflunine.', 'Duration of Treatment:', 'Subjects will be allowed to receive EV or comparator until discontinuation criteria are met or upon', 'study termination, or study completion, whichever occurs first.', 'Enppoints for Evaluation:', 'Primary', 'os', 'Secondary', 'PFS1 per RECIST V1.1', 'ORR (complete response [CR] + PR) per RECIST V1.1', 'DCR (CR + PR + stable disease [SD]) per RECIST V1.1', 'DOR per RECIST V1.1', 'Safety variables (e.g., AEs, laboratory tests, vital sign measurements, 12-lead', 'electrocardiogram and ECOG PS)', 'QOL and PRO parameters (QLQ-C30 and EQ-5D-5L)', 'Exploratory', 'Exploratory genomic and/or other biomarkers in tumor tissue and in peripheral blood that may', 'correlate with treatment outcome, including Nectin-4 expression', 'Selected plasma or serum concentrations of TAb, ADC and MMAE', 'Incidence of ATA to EV', 'PFS2 per RECIST V1.1', 'HRU', 'Statistical Methods:', 'Approximately 600 subjects will be randomized in a 1:1 ratio to 2 treatment arms: Arm A (EV) and', 'Arm B (docetaxel, paclitaxel or vinflunine). Randomization will be stratified by:', 'Liver Metastasis (yes/no)', 'ECOG PS (0 VS 1)', 'Regions of the world (US, Western Europe and Rest of World)', 'Sample Size Justification:', 'Approximately 600 subjects (with 10% dropout rate and 1 interim analysis) will be randomized in', 'a 1:1 ratio to receive EV or chemotherapy.', 'Primary endpoint: os', 'One-sided 2.5% Type I error; 85% Power', 'OS Assumption: hazard ratio (HR) = 0.75 (median OS of 10.7m VS 8m, for EV VS', 'Chemotherapy arm)', 'A formal interim efficacy analysis will be done when approximately 65% of deaths have', 'occurred.', 'Primary analysis will occur at about 439 os events', \"For planned interim efficacy analysis, a group sequential design using the O'Brien-Fleming\", 'boundaries as implemented by Lan-DeMets method will be used to control the overall 1-sided', '0.025 type I error. If the interim analysis demonstrates a statistically significant outcome for EV in', 'efficacy, the study may be stopped and concluded due to efficacy.', '14 Sep 2020', 'Astellas', 'Page 29 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}